 Creating quality 
outcomes through our 
financial strength
Highlights 2016
Financial
2016 2015
Reported 
growth
Growth at 
constant 
currency
1
Group revenue (£ million) 82.6 68.6 20% 13%
Adjusted
2
 operating margin (%) 23.9 25.4 (150bps) –
Adjusted
2
 profit before tax (£ million) 19.7 17.4 13% –
Profit before tax (£ million) 19.1 17.0 12% –
Adjusted
2
 diluted earnings per share (p) 7.66 6.86 12% –
Diluted earnings per share (p) 7.38 6.68 10% –
Net operating cash flow
3
  
pre-exceptional items (£ million) 22.3 22.5 (1%) –
Net cash (£ million)
4
 51.1 34.2 49% –
Proposed final dividend of 0.62p per share, making a total dividend for the year 
of 0.92p (2015: 0.80p), up 15%
Business
 e Good sales progress across all Business Units:
• Branded Distributed up 42% to £20.8 million (2015: £14.6 million), and up 30% 
at constant currency
• Branded Direct up 10% to £24.6 million (2015: £22.3 million), and up 3% 
at constant currency
• OEM up 16% to £32.1 million (2015: £27.7 million), and up 12% 
at constant currency
• Bulk Materials up 33% to £5.2 million (2015: £3.9 million),  
and up 21% at constant currency
 e Continued strong performance in the US with LiquiBand
®
 tissue adhesive range:
• Revenues up 56% to £12.5 million (2015: £8.0 million) and 39% 
at constant currency
• As at 31 December 2016, market share by volume
5
 increased to 23%  
(June 2016: 19%) and initial 20% target share achieved in the combined hospital 
and non-hospital market
 e Successful launch of antimicrobial and atraumatic foam dressings into Europe
 e Antimicrobial dressing revenues including both silver and PHMB 
(Polyhexamethylene Biguanide) up 13% to £17.5 million (2015: £15.5 million) 
and 9% at constant currency
 e Sales of the hernia mesh fixation device, LiquiBand
®
 Fix8
™
 increased 73% 
to £1.7 million (2016: £1.0 million), 68% at constant currency, and is in use 
in 25 countries; now preparing for Pre Market Approval (PMA) in the US
 e German and Czech RESORBA
®
 business up 15% to £13.1 million 
(2015: £11.3 million) and 4% at constant currency
 e Successful launch of RESORBA
®
 sutures into the US
 e ActivHeal
®
 business declined 5% to £6.0 million (2015: £6.4 million)
1
 Constant currency removes the effect of currency movements by 
re-translating the current period’s performance at the previous 
period’s exchange rates
2
 All items are shown before exceptional items which were 
£0.4 million (2015: £nil) and amortisation of acquired intangible 
assets which, in 2016, were £0.2 million (2015: £0.4 million) as 
defined in the financial review
3
 Operating cash flow is arrived at by taking the operating profit for 
the period before exceptional items of £0.4 million (2015: £nil), 
depreciation, amortisation, working capital movements and other 
non cash items
4
 Net cash is defined as cash and cash equivalents plus short term 
investments less financial liabilities and bank loans
5
 Data supplied by Global Healthcare Exchange
Group revenue
£82.6m
(2015: £68.6m)
Adjusted
2
 diluted  
earnings per share
7.66p
(2015: 6.86p)
Adjusted
2
 profit 
before tax
£19.7m
(2015: £17.4m)
Net cash
4
£51.1m
(2015: £34.2m)
Company Overview
Strategic Report  
Governance
Financial Statements
01
Advanced Medical Solutions Group plc 
Annual Report 2016
